Pierfrancesco Tassone
YOU?
Author Swipe
Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC Open
Background Immune checkpoint inhibitors (ICIs) redefined the treatment of non-small cell lung cancer (NSCLC) but their efficacy in elderly and frail patients remains unclear due to immune-senescence and the underrepresentation of these pop…
View article: CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy Open
Background: Chimeric antigen receptor (CAR) T-cell therapy has transformed the therapeutic landscape for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Our study aims to describe the clinical outcomes of CAR T-cell the…
View article: Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin’s Lymphoma
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin’s Lymphoma Open
Background: Lymphomas account for approximately 10% of cancers diagnosed during pregnancy, with Hodgkin’s lymphoma being the most common. However, non-Hodgkin lymphomas, including primary mediastinal large B-cell lymphoma (PMBCL), also rep…
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis Open
The sequencing of the human genome in 2003 marked a transformative shift from a one-size-fits-all approach to personalized medicine, emphasizing patient-specific molecular and physiological characteristics. Advances in sequencing technolog…
View article: miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma
miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma Open
[This corrects the article DOI: 10.1016/j.omtn.2019.02.023.].
Immune-related [18F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications Open
Background Direct comparisons between [ 18 F]FDG PET/CT findings and clinical occurrence of immune-related adverse events (irAEs) based on independent assessments of clinical and imaging features in patients receiving immune checkpoint inh…
Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients Open
Immunotherapy represents an emergent and heterogeneous group of anticancer treatments harnessing the human immune-surveillance system, including immune-checkpoint inhibitor monoclonal antibodies (mAbs), Chimeric Antigen Receptor T Cells (C…
View article: An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma Open
Multiple myeloma (MM) is an incurable malignancy characterized by altered expression of coding and noncoding genes promoting tumor growth and drug resistance. Although the crucial role of long noncoding RNAs (lncRNAs) in MM is clearly esta…
A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer Open
Targeting non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), has recently emerged as a promising strategy for treating malignancies and other diseases. In recent years, the development of ncRNA-based…
View article: TERRA G‐quadruplex stabilization behind the anti‐multiple myeloma activity: Novel insights about resveratrol pleiotropic effects
TERRA G‐quadruplex stabilization behind the anti‐multiple myeloma activity: Novel insights about resveratrol pleiotropic effects Open
Resveratrol (RSV) is a nutraceutical compound belonging to the nonflavonoid polyphenol family, whose antioxidants, anti‐inflammatory, and antitumoral properties have been widely investigated. The ability of RSV to provide beneficial effect…
View article: Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study Open
PURPOSE The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non–small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti–PD-(L)1, …
Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) Open
Despite the recent availability of immune checkpoint inhibitors, not all patients affected by Non-Small-Cell Lung Cancer (NSCLC) benefit from immunotherapy. The reason for this variability relies on a variety of factors which may allow for…
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience Open
Real-world TIC incidence is higher compared to randomized clinical trials and biomarkers with potential predictive value aren't available. Our preliminary data, as proof of concept, could suggest a predictive role of pharmacogenomic approa…
Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC) Open
Despite the recent availability of immune checkpoint inhibitors, not all patients affected by Non-Small Cell Lung Cancer (NSCLC) benefit from immunotherapy. The reason for this variability relies to a variety of factors which may allow the…
View article: Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma Open
The identification of biomarkers for predicting inter-individual sorafenib response variability could allow hepatocellular carcinoma (HCC) patient stratification. SNPs in angiogenesis- and drug absorption, distribution, metabolism, and exc…
View article: The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis Open
Considering all aEOC subgroups, the best therapeutical option was identified as PARPi plus chemotherapy and/or antiangiogenetic agents, suggesting the relevance of combinatory approaches based on molecular profile. This work underlines the…
View article: <scp>UMG1</scp>/<scp>CD3ε‐bispecific T‐cell</scp> engager redirects T‐cell cytotoxicity against diffuse large <scp>B‐cell</scp> lymphoma
<span>UMG1</span>/<span>CD3ε‐bispecific T‐cell</span> engager redirects T‐cell cytotoxicity against diffuse large <span>B‐cell</span> lymphoma Open
Summary UMG1 is a unique epitope of CD43, not expressed by normal cells and tissues of haematopoietic and non‐haematopoietic origin, except thymocytes and a minority (<5%) of peripheral blood T lymphocytes. By immunohistochemistry analysis…
Targeting non-coding RNAs: Perspectives and challenges of in-silico approaches Open
The growing information currently available on the central role of non-coding RNAs (ncRNAs) including microRNAs (miRNAS) and long non-coding RNAs (lncRNAs) for chronic and degenerative human diseases makes them attractive therapeutic targe…
Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice Open
Lynch syndrome (LS), also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), is an autosomal dominant cancer syndrome which causes about 2–3% of cases of colorectal carcinoma. The development of LS is due to the genetic and epige…
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity Open
Background The optimal strategy for the treatment of recurrent and/or advanced endometrial cancer is still undefined. Recently, despite the lack of any predictive biomarker, the combination of pembrolizumab with lenvatinib has improved sur…
View article: Genetic biomarkers of sorafenib response in patients with hepatocellular carcinoma
Genetic biomarkers of sorafenib response in patients with hepatocellular carcinoma Open
Purpose: The identification of biomarkers for predicting inter-individual sorafenib response variability could allow hepatocellular carcinoma (HCC) patients stratification. SNPs in angiogenesis- and drug absorption, distribution, metabolis…
View article: Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study Open
Background We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221) with a full phosphorothioate (PS)-modified backbone. This agent downregulated miR-221, demonstrated anti-tumor activity against human xenograft…
Hit identification of novel small molecules interfering with <i>MALAT1</i> triplex by a structure‐based virtual screening Open
Nowadays, RNA is an attractive target for the design of new small molecules with different pharmacological activities. Among several RNA molecules, long noncoding RNAs (lncRNAs) are extensively reported to be involved in cancer pathogenesi…